会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • T CELL RECEPTORS
    • 细胞受体
    • WO2015022520A1
    • 2015-02-19
    • PCT/GB2014/052464
    • 2014-08-12
    • IMMUNOCORE LIMITED
    • SU, QinMOLLOY, PeterLIDDY, Nathaniel
    • C07K14/05
    • C07K14/05A61K39/12A61K2039/6056C07K14/7051C07K16/2809C07K2317/622C07K2319/00C07K2319/03C07K2319/30C12N7/00C12N2710/16222C12N2710/16234C12N2710/16271
    • The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted CLGGLLTMV peptide derived from the LMP2A protein from Epstein Barr Virus (EBV). TCRs of the invention comprise a TCR alpha chain variable domain and/or a TCR beta variable domain. Certain preferred TCRs also bind the natural peptide variants SLGGLLTMV and CLGGLITMV presented as a peptide-HLA-A2 complex. The TCRs of the invention demonstrate excellent specificity profiles for those LMP2A epitopes and have binding affinities for the complex which result in an enhanced ability to recognize the complex compared to a soluble reference TCR having the extracellular sequence of the native EBV LMP2A TCR alpha chain given in Figure 3 (SEQ ID No: 4) and the extracellular sequence of the native EBV LMP2A TCR beta chain given in Figure 4 (SEQ ID No: 5)
    • 本发明涉及结合源自爱泼斯坦巴尔病毒(EBV)的LMP2A蛋白的HLA-A2限制性CLGGLLTMV肽的T细胞受体(TCR)。 本发明的TCR包含TCRα链可变结构域和/或TCRβ可变结构域。 某些优选的TCR还结合天然肽变体SLGGLLTMV和CLGGLITMV作为肽HLA-A2复合物。 本发明的TCR表现出对于这些LMP2A表位的优异的特异性谱,并且与具有天然EBV LMP2ATCRα链的细胞外序列的可溶性参考TCR相比,复合物具有增强的识别复合物的能力的结合亲和力,其给出在 图3(SEQ ID No:4)和图4(SEQ ID No:5)给出的天然EBV LMP2ATCRβ链的细胞外序列